Efficiency of vanillin in impeding metabolic adaptability and virulence of Candida albicans by inhibiting glyoxylate cycle, morphogenesis, and biofilm formation

سال انتشار: 1399
نوع سند: مقاله ژورنالی
زبان: انگلیسی
مشاهده: 50

فایل این مقاله در 8 صفحه با فرمت PDF قابل دریافت می باشد

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

JR_CUMM-6-1_001

تاریخ نمایه سازی: 11 آذر 1402

چکیده مقاله:

Background and Purpose: Candida albicans is the fourth most common cause of nosocomial fungal infections across the world. The current drug regimens are suffering from such drawbacks as drug resistance, toxicity, and costliness; accordingly, they highlight the need for the discovery of novel drug agents. The metabolic adaptability under low-carbon conditions and expression of functional virulence traits mark the success of pathogens to cause infection. The metabolic pathways, such as glyoxylate cycle (GC), enable C. albicans to survive under glucose-deficient conditions prevalent in the hostile niche. Therefore, the key enzymes, namely isocitrate lyase (ICL) and malate synthase (MLS), represent attractive agents against C. albicans. Similarly, virulence traits, such as morphogenesis and biofilm formation, are the crucial determinants of C. albicans pathogenicity. Regarding this, the present study was conducted to uncover the role of vanillin (Van), a natural food flavoring agent, in inhibiting GC, yeast-to-hyphal transition, and biofilm formation in human fungal pathogen C. albicans. Materials and Methods: For the determination of hypersensitivity under low-glucose conditions, phenotypic susceptibility assay was utilized. In addition, enzyme activities were estimated based on crude extracts while in-silico binding was confirmed by molecular docking. The assessment of morphogenesis was accomplished using hyphalinducing media, and biofilm formation was estimated using calcofluor staining, MTT assay, and biomass measurement. Additionally, the in vivo efficacy of Van was demonstrated using Caenorhabditis elegans nematode model. Results: Based on the results, Van was found to be a potent GC inhibitor that phenocopied ICL۱ deletion mutant and displayed hypersensitivity under low-carbon conditions. Accordingly, Van facilitated the inhibition of ICL and MLS activities in vitro. Molecular docking analyses revealed the in-silico binding affinity of Van with Icl۱p and Mls۱p. Those analyses were also confirmative of the binding of Van to the active sites of both proteins with better binding energy in comparison to their known inhibitors. Furthermore, Van led to the attenuation of such virulence traits as morphogenesis, biofilm formation, and cell adherence. Finally, the antifungal efficacy of Van was demonstrated by the enhanced survival of C. elegans with Candida infection. The results also confirmed negligible hemolytic activity on erythrocytes. Conclusion: As the findings of the present study indicated, Van is a persuasive natural compound that warrants further attention to exploit its anticandidal potential

نویسندگان

Venkata Saibabu

Amity Institute of Biotechnology, Amity University Haryana, Gurugram, India

Zeeshan Fatima

Amity Institute of Biotechnology, Amity University Haryana, Gurugram, India

Kamal Ahmad

Department of Pharmaceutical Chemistry, Jamia Hamdard, New Delhi, India

Luqman Khan

DDepartment of Biosciences, Jamia Millia Islamia, New Delhi, India

Saif Hameed

Amity Institute of Biotechnology, Amity University Haryana, Gurugram, India

مراجع و منابع این مقاله:

لیست زیر مراجع و منابع استفاده شده در این مقاله را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود مقاله لینک شده اند :
  • Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent ...
  • Prasad R, Kapoor K. Multidrug resistance in yeast Candida. Int ...
  • Saibabu V, Fatima Z, Khan LA, Hameed S. Therapeutic potential ...
  • World Health Organization. Summary of evaluations performed by the joint ...
  • Fleck CB, Schöbel F, Brock M. Nutrient acquisition by pathogenic ...
  • Van Schaik EJ, Tom M, Woods DE. Burkholderia pseudomallei isocitrate ...
  • Ebel F, Schwienbacher M, Beyer J, Heesemann J, Brakhage AA, ...
  • Krátký M, Vinšová J. Advances in mycobacterial isocitrate lyase targeting ...
  • Lorenz MC, Fink GR. Life and death in a macrophage: ...
  • Lorenz MC, Fink GR. The glyoxylate cycle is required for ...
  • Ansari MA, Fatima Z, Ahmad K, Hameed S. Monoterpenoid perillyl ...
  • Webb W, Sali A. Protein structure modeling with MODELLER. Methods ...
  • Wu S, Skolnick J, Zhang Y. Ab initio modeling of ...
  • Ahmad K, Bhat AR, Athar F. Pharmacokinetic evaluation of callistemon ...
  • Saibabu V, Fatima Z, Ahmad K, Khan LA, Hameed S. ...
  • Ebel F, Schwienbacher M, Beyer J, Heesemann J, Brakhage AA, ...
  • Berman J, Sudbery PE. Candida albicans: a molecular revolution built ...
  • Okoli I, Coleman JJ, Tampakakis E, An WF, Holson E, ...
  • Manoharan RK, Lee JH, Kim YG, Kim SI, Lee J. ...
  • نمایش کامل مراجع